Tuberculosis chemotherapy in the 21st century: Back to the basics

  title={Tuberculosis chemotherapy in the 21st century: Back to the basics},
  author={J. M. Joshi},
  journal={Lung India : Official Organ of Indian Chest Society},
  pages={193 - 200}
  • J. Joshi
  • Published 1 July 2011
  • Medicine, Biology
  • Lung India : Official Organ of Indian Chest Society
The key to successful elimination of tuberculosis (TB) is treatment of cases with optimum chemotherapy. Poor chemotherapy over time has led to drug-resistant disease. Drug resistance of Mycobacterium tuberculosis develops by the selective growth of resistant mutants. The incidence of drug-resistant cases depends on the number of bacilli and the drug-resistant mutants in the lesion. The latter is low for individual drugs and even lower for two and three drugs. Therefore, use of combination… 

Tables from this paper

New Insights in Design and Development of Antitubercular Drugs

The vaccine and peptide-based conjugates are recent developments against Mycobacterium for selective and specific targeting to the desired tissues in the treatment of multidrug-resistant tuberculosis.

Tuberculosis - present medication and therapeutic prospects.

Despite a 22% decrease in the tuberculosis fatality rate observed between 2000 and 2015, the disease remains one of the ten prime causes of death worldwide and increasing bacterial resistance and expensive, prolonged therapies are the main reasons for efforts to find effective drugs or antituberculotic regimens.

Drug targets exploited in Mycobacterium tuberculosis: Pitfalls and promises on the horizon.

Extra-Pulmonary TB

This chapter includes the global scenario of TB patients and brief description of TB history, its pathogenesis, types, diagnosis tests, emergence of MDR (multi drug resistance) and XDR (extensively drug resistance).

Analysing non-synonymous mutations in XDR and MDR tuberculosis drugs

Antituberculosis Targeted Drug Delivery as a Potential Future Treatment Approach

An overview on the history of tuberculosis and the currently available treatment options is provided, followed by discussions on the discovery of new antituberculosis drugs and active and passive targeting approaches against Mycobacterium tuberculosis.


It was found that early improvement of symptoms, adverse effects of anti TB drugs used, and financial burden were also important causes of treatment interruption with subsequent adverse consequences, which could have led to emergence of drug resistant tuberculosis.

Extrapulmonary drug-resistant tuberculosis at a drug-resistant tuberculosis center, Mumbai: Our experience – Hope in the midst of despair!

  • U. DesaiJ. Joshi
  • Medicine
    Lung India : official organ of Indian Chest Society
  • 2019
Background: Drug-resistant tuberculosis (DR-TB) is a global problem with only 52% reported cure rate. Extrapulmonary (EP) DR-TB poses a formidable diagnostic, therapeutic challenge. We aimed to study

Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance

Using experimental evolution and whole-genome sequencing, it is found that alternating drugs slows the rate of increase in resistance compared with single-drug treatments, by constraining resistance mutations with trade-offs in resistance to a second drug.

The chamber of secretome in Mycobacterium tuberculosis as a potential therapeutic target.

The present review demonstrates the current status of therapeutics against MTB and focuses on the function and cruciality of T7SS along with other secretory systems as a promising therapeutic target against Tuberculosis.



Treatment of multidrug-resistant tuberculosis.

  • D. Cohn
  • Medicine, Biology
    The Journal of hospital infection
  • 1995

Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis.

Control of drug-resistant tuberculosis.

Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran.

The isolation of TDR strains from MDR-TB patients from different regional countries is alarming and underlines the possible dissemination of such strains in Asian countries.

New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes

Purpose of review The aim is to review briefly the problems related to treatment of drug-susceptible and drug-resistant tuberculosis (TB), describe recent advances in the development of new drugs and

Drug-resistant tuberculosis: laboratory issues. World Health Organization recommendations.

  • B. VareldzisJ. Grosset A. Kochi
  • Medicine
    Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
  • 1994

Jaundice due to anti-tuberculous drugs--a dose related phenomenon.

One patient, who was staredon weight adjusted dosage of anti-TB drugs developed jaundice which was probably due to isoniazed hypersensitivity, in accordance with IUAT recommendations.

Advances in the diagnosis and treatment of tuberculosis.

Important changes in the philosophy of treatment are focused on, emphasizing the responsibility of the provider to assure successful completion of treatment, and on the roles of existing anti-TB agents and newer drugs such as rifabutin, rifapentine, and fluoroquinolones.

Management of Tuberculosis Meningitis

Various chemotherapeutic approaches are available for tuberculosis meningitis but it appears the use of rifampicin (rifampin) with isoniazid-containing regimens gives the best results.

Fast action urged to halt deadly TB.

  • J. Wise
  • Medicine
    Bulletin of the World Health Organization
  • 2007
Two new rapid diagnostic tests for multidrug-resistant tuberculosis (MDR-TB) are to be piloted in South Africa, dramatically cutting diagnosis time from two or more months to just two days, and will be the first time new technology is used to tackle the crisis of drug- resistant tuberculosis in Africa.